Benevolent AI (Benevolent AI) Inventories, Inventories Adjustments : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Benevolent AI Inventories, Inventories Adjustments?

Benevolent AI's Inventories, Inventories Adjustments for the quarter that ended in Dec. 2023 was $0.00 Mil.

Benevolent AI Inventories, Inventories Adjustments Historical Data

The historical data trend for Benevolent AI's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benevolent AI Inventories, Inventories Adjustments Chart

Benevolent AI Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Inventories Adjustments

Get a 7-Day Free Trial

Benevolent AI Quarterly Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Inventories, Inventories Adjustments	Get a 7-Day Free Trial				-	-	-	-	-

Benevolent AI Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.

Benevolent AI (Benevolent AI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (GREY:BAIVF) » Definitions » Inventories, Inventories Adjustments

Comparable Companies

Traded in Other Exchanges

BAI:Netherlands 2XA:Germany

Address

4-8 Maple Street, London, GBR, W1T 5HD

Website

https://www.benevolent.com

Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.